In short
Clinical trials investigating Venlafaxine Hydrochloride are studying how it is used in depression-related research, including treatment planning and antidepressant stopping strategies. These trials look at outcomes such as symptom improvement, treatment success, and how well people can discontinue antidepressants. The target groups include adults with depressive disorder and people whose depression is currently in remission.
Key points
- Clinical trials investigating Venlafaxine Hydrochloride are focused on depression-related research. One Phase 3 study looks at safe antidepressant discontinuation in people with currently remitted depressive disorders. Another Phase 3 study tests a personalized medicine approach for people with depressive disorder who are starting a new antidepressant after prior treatment failure. The main outcomes include symptom remission, depression score changes, and whether people can stop treatment successfully. Together, these trials study treatment planning, stopping strategies, and outcomes in adults with depression or remission.
Trial overview
Two authorised Phase 3 clinical trials include Venlafaxine Hydrochloride in research on depressive disorders. Both studies are interventional, which means researchers are testing a planned treatment strategy and measuring the results.
One study focuses on people with currently remitted depressive disorders and looks at antidepressant discontinuation. The other study focuses on people with depressive disorder who are starting a new antidepressant after prior treatment failure.
Safe discontinuation in remitted depression
The first trial is titled SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS. It is authorised, Phase 3, and plans to enroll 150 participants with currently remitted depressive disorders.
This study compares hyperbolic tapering with linear tapering. Tapering means lowering the medicine step by step before stopping it. The study checks whether people can discontinue the antidepressant successfully and stay off it during the 16 weeks after stopping.
The primary outcome is the proportion of participants who fail to discontinue the antidepressant or restart it during the 16-week follow-up. Failure to discontinue is defined as continuing the medication beyond the planned tapering schedule, with only a small tolerance period allowed. This may happen because of withdrawal symptoms or because depressive or anxiety symptoms return.
The listed antidepressants in this trial include several medicines used in oral form, and Venlafaxine Hydrochloride is part of the broader research topic for this article.
Personalized treatment after prior failure
The second trial is the PREDICT clinical trial, which is also authorised and in Phase 3. It plans to enroll 240 participants with depressive disorder.
This study evaluates a pre-emptive pharmacogenetic strategy for antidepressant selection. Pharmacogenetic testing means looking at genetic markers to help choose a medicine before treatment starts. The study compares this personalized approach with standard clinical practice in people who are beginning a new antidepressant after a previous treatment did not work.
Venlafaxine Hydrochloride appears in the trial’s list of possible antidepressant options as Venlafaxina Retard Sandoz 75 mg, a prolonged-release capsule. The trial does not study Venlafaxine Hydrochloride alone; it is part of a larger treatment-selection strategy.
Main outcomes and measures
In the discontinuation trial, the main outcome is whether participants can stop the antidepressant and avoid restarting it during the follow-up period. This outcome helps researchers understand how well different tapering methods support safe stopping.
In the PREDICT trial, the main outcome is symptom remission after starting a new antidepressant treatment. Researchers measure this using changes in PHQ-9 and MADRS scores, which are tools for rating depression severity.
These outcomes focus on two important questions: can treatment be stopped safely, and can treatment choice be improved for better symptom control?
Who can participate
The first study is for adults with currently remitted depressive disorders. This means people whose depression is currently improved enough to be considered in remission.
The second study is for patients with depressive disorder who are starting a new antidepressant after a prior therapy failed. The study also uses demographic information, clinical information, and data about other medicines taken at the same time.
- Remitted depression group: people whose depressive disorder is currently not active, so researchers can study stopping antidepressants safely.
- Depressive disorder group: people who need a new antidepressant after a previous treatment failure, so researchers can test a personalized selection strategy.
What these trials may mean for patients
These studies are not simple drug comparison trials; they test treatment strategies in real clinical situations. One strategy asks whether antidepressants can be stopped more safely after remission, while the other asks whether treatment choice can be improved using genetic and clinical information.
For patients, the most important point is that the trials are looking at practical outcomes such as staying well, avoiding symptom return, and matching treatment to the person. The available data show that Venlafaxine Hydrochloride is part of this broader depression research, especially in treatment planning and antidepressant selection.